Compumedics Ltd (ASX:CMP) has strengthened its sales figures to $4.3 million, after receiving orders from China which are back to pre-pandemic levels.
In addition, the company had also booked a 700,000 sales order to supply, among other items, its new Okti® neurological monitoring system to the Royal Children’s Hospital in Melbourne.
Compumedics re-affirms existing revenue guidance of more than $40 million for FY23, with second-half EBITDA of about $2 million and FY23 underlying EBITDA of about $1 million.
Updates from other ventures
Compumedics' commercialisation of Somfit consumer sleep devices continues to progress in Australia and the US towards initial product and software as a service (SaaS).
The company is working towards the delivery of its second MEG sale and its first MEG contract in Asia to Tianjin Normal University (TJNU) in China.
Furthermore, Compumedics is reviewing its MEG strategy with its partners in Korea, China and the US and will provide a further update to the market in due course.
About Compumedics
Compumedics is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for sleep, brain, and ultrasonic blood flow monitoring applications.
The company owns US-based Neuroscan and Germany-based DWL Elektronishe GmbH.
In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and the Asia Pacific, Europe, and the Middle East.